CareCloud's Clean Slate: Series B Redemption and a Pivot into AI Compliance
With a simplified balance sheet, a new compliance market, and an AI roadmap, MTBCP is positioning for a stronger second half.
MTBCP · Earnings Call · 2026-08-06
A Quarter of Structural Change
CareCloud's Q2 2026 report was more about reshaping the foundation than headline numbers. Revenue rose 16% year-over-year to $31.9 million, but the bigger story is what CEO Stephen Snyder called "the most significant simplification of CareCloud's balance sheet since our IPO" — the full redemption of the Series B preferred stock, funded through a $50 million credit facility. That move eliminates roughly $3.3 million in annual preferred dividends and, as Snyder put it, "the preferred overhang that shaped our capital structure for many years." The immediate EPS benefit is visible: with the Series B gone, starting in Q3 "far more of every dollar of net income we generate flows through to our common shareholders." This is a classic Redemption activity story — but here it's the company's own capital structure, not an investor queue.
That single step eliminates approximately $3.3 million of annual preferred dividends, and with it the preferred overhang that shaped our capital structure for many years.
The trade-off is higher interest expense, which depressed GAAP net income to $1.1 million (versus $2.9 million a year ago). But management frames this as deliberate — "we traded near-term reported earnings for durable earnings power" — and the market is being asked to look through the investment phase to a harvest in H2.
Compliance: A New Market, A New Playbook
The most distinctive move this quarter was the acquisition of Empower Healthcare and Compliance Partners, a compliance and audit defense firm. This takes CareCloud into an entirely new category — commercial readiness for the provider's regulatory and audit burden. As Snyder explained, providers are "contending with rising payer scrutiny and audit activity, industry-wide denial rates, expanding privacy and security obligations." The acquisition is small from a financial perspective, but strategically significant: it opens a cross-selling channel both directions. Empower's founder, Mitch Brie, already referred business that represents "about 10% of our overall revenue on an annualized basis."
“Part of it will be taking our existing customer base and cross-selling that customer base into the SaaS platform. The other part will be being able to leverage cross-selling from the perspective of the existing Empower clients and cross-selling our revenue cycle management services and EHR solution into that base.” — Stephen Snyder, Chief Executive Officer · 2026-08-06
That's a textbook Cross selling motion, and it's one the company has executed more than 20 times. What's new is the market itself: compliance services are becoming a recurring, subscription-based product. CareCloud plans to launch AI-enabled compliance software in the fall, converting what was a manual professional service into a tiered SaaS offering. This is exactly the kind of launch readiness the market has been watching for—the question is whether the fall launch sticks.
AI: From Internal Tool to Revenue Driver
The AI strategy is the connective tissue across all three tracks: internal efficiency, embedded product features, and standalone AI products. The most tangible progress is on stratusAI Front Desk (an AI voice agent), which is "continuing to sign new business," and on the AI prior authorization and AI-assisted coding tools, which are "on track to bring to market this year." Hadi Chaudhry detailed specific platform commitments met — parity between legacy systems and RCM Cloud, integrations for Wellsoft, and the rollout of an AI candidate matching engine in Marketware. The deeper narrative is consolidation: CareCloud is "moving towards a single modular platform on a shared back end" so every new AI capability can be deployed everywhere at once.
“We continue to sign up more deals on from stratusAI and other AI products. We are extensively in the implementation phase, and I think when we get to a point of where the numbers, the AI specific revenue numbers are scalable enough that we should be able to start disclosing, we will separate it out.” — Hadi Chaudhry, Chief Strategy Officer · 2026-08-06
The revenue from AI is still early, but the strategic direction is clear — and the market context supports it. Industry surveys show physician AI adoption has more than doubled over three years, and administrative burden is the largest opportunity. CareCloud is betting that its integrated platform (EHR + RCM + compliance) becomes the trusted AI layer for providers.
Guidance and the Second-Half Harvest
Management reaffirmed full-year guidance of $128-132M revenue, $29-31M adjusted EBITDA, and $0.20-0.23 EPS. The implied H2 ramp is significant: Q2 revenue of $31.9M must rise to roughly $33-34M per quarter, and adjusted EBITDA from $5.9M to a much higher run-rate. The levers are concrete — lower amortization, reduced integration costs, the end of Series B dividends, and continuing cross-sell wallet expansion. As Snyder put it in his answer on seasonality, "part of that is really seasonality. The other part relates to the fact that we will continue to layer growth on top of the existing business.” The risk is execution: the market wants to see the AI and compliance revenue lines separate out and scale. If the H2 numbers deliver, the clean capital story plus a new TAM could re-rate the shares.
“We'll need to go from roughly $32 million in Q2 to $33 million, $34 million per quarter in the balance of the year to achieve our guidance. And we feel comfortable that that is very doable.” — Stephen Snyder, Chief Executive Officer · 2026-08-06
CareCloud enters the second half with 40,000+ providers, nine quarters of GAAP profitability, a freshened capital structure, and a foothold in one of healthcare's fastest-growing pain points. Whether that's enough to turn the stock around depends on how convincingly the AI and compliance narratives convert into reported revenue.